May, 2016

The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women


Authors: Schalkwijk S, Colbers A, Konopnicki D, et al.

Published in: Aids. 2016; 30(8):1239-1244

Abstract: To describe the pharmacokinetics of abacavir 600 mg once daily (q.d.) in HIV-1-positive women during pregnancy and postpartum.


Apr, 2016

High prevalence of herpes simplex virus (HSV)- type 2 co-infection among HIVpositive women in Ukraine, but no increased HIV mother-to-child transmission risk


Authors: Aebi-Popp K, Bailey H, Malyuta R, Volokha A, Thorne C.

Published in: BMC Pregnancy Childbirth. 2016;16:94.



Apr, 2016

Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption” has been accepted for publication in AIDS


Authors: Ananworanich J, Melvin D, Ramos Amador JT, Childs T, Medin G, Boscolo V, Compagnucci A, Kanjanavanit S, Montero S, Gibb DM, on behalf of the PENTA 11 study group.

Published in: AIDS: 24 April 2016 – Volume 30 – Issue 7 – p 1075–1081



Mar, 2016

First reported use of elvitegravir and cobicistat during pregnancy


Authors: Schalkwijk S, Colbers A, Konopnicki D, et al.

Published in: Aids. Vol 30. England2016:807-808.


Mar, 2016

Children and young people with perinatal HIV in Europe: epidemiological sitation in 2014 and implications for the future


Authors: Writing group for the Kids to Adults Working Group and Data Management and Harmonisation Group in EuroCoord.

Published in: Euro Surveill. 2016; 21: ES.201621.10.30162.

Abstract: Accurate ascertainment of the number of children living with human immunodeficiency virus (HIV) is important to plan paediatric and adolescent health services. In Europe, the first generation of perinatally HIV-infected survivors are transferring to adult care and their health needs are unknown. We undertook an online survey of HIV cohort studies participating in the EuroCoord Network of Excellence to ascertain the number of perinatally HIV-infected (pHIV) patients included, to compare it with those published by the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO) and to assess the ability of countries to follow up pHIV patients after transfer to adult care. At the end of 2013, 16 countries in EuroCoord reported 8,229 pHIV patients in follow-up in cohorts, compared with 5,160 cumulative diagnoses reported by the ECDC in the same area. Follow-up of pHIV patients after transfer to adult care varied. It is likely that the number of diagnoses of perinatal HIV reported to ECDC is an underestimate, although this varies by country. Further work is needed to refine estimates and encourage follow-up in adult HIV cohorts to investigate long-term outcomes and improve the care of the next generation of children with HIV.



Mar, 2016

Children and young people with perinatal HIV in Europe: epidemiological situation in 2014 and implications for the future.


Authors: Kids to Adults Working Group and Data Management and Harmonisation Group in EuroCoord.

Published in: Eurosurveillance 2016; 21(10):pii=30162.



Feb, 2016

The European Paediatric Mycology Network (EPMyN): Towards a Better Understanding and Management of Fungal Infections in Children


Author: Adilia Warris

Published in: Curr Fungal Infect Rep. 2016;10:7-9.

Abstract: The European Paediatric Mycology Network (EPMyN) was launched in 2014 to create a European platform for research and education in the field of paediatric mycology. The EPMyN aims to address the lack of paediatric specific evidence and knowledge needed to (1) improve the management and outcome of invasive fungal infections in children and neonates and to (2) enhance and develop paediatric anti-fungal stewardship programmes.

This article is published with open access at



Jan, 2016

Response to Planned Treatment Interruptions in HIV-infection varies across Childhood in the PENTA 11 Trial


Published in: Aids. 2010;24(2):231-241.



Dec, 2015

When information does not suffice: young people living with HIV and communication about ART adherence in the clinic.


Despite mounting evidence recommending disclosure of human immunodeficiency virus (HIV) status to young people with perinatally acquired HIV as a central motivating factor for adherence to antiretroviral therapy, many young people continue to experience disclosure as a partial event, rather than a process. Drawing from two longitudinal, interview-based qualitative studies with young people living with HIV (aged 10–24) in five different countries in low and high income settings, we present data regarding disclosure and information about HIV in the clinic. The article highlights the limits of discussions framing disclosure and patient literacy, and young people’s reluctance to voice their adherence difficulties in the context of their relationships with clinical care teams. We suggest that a clinician-initiated, explicit acknowledgment of the social and practical hurdles of daily adherence for young people would aid a more transparent conversation and encourage young people to disclose missed doses and other problems they may be facing with their treatment. This may help to reduce health harms and poor adherence in the longer-term.

Authors: Bernays, S. Paparini, D. Gibb & J. Seeley

Published in: Vulnerable Children and Youth Studies: An International Interdisciplinary Journal for Research, Policy and Care. E-pub Dec 2015



Nov, 2015

Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand.


Authors: European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord.

Published in: Antiviral Therapy 2016; 21(4): 353-8